Targetcancer Foundation Inc
- Assets
- $523.9k
- Revenue
- $676.5k
- Investments
- $0.0
- Employees
- 4
- Location
- Cambridge, MA
- Founding
- 08/2009
- Data as of
- 01/2024
- EIN
- 26-4510094
Organization Overview
Targetcancer Foundation Inc is located in Cambridge, MA. The organization was established in 2009. According to its NTEE Classification (H30) the organization is classified as: Cancer Research, under the broad grouping of Medical Research and related organizations. As of 01/2024, Targetcancer Foundation Inc employed 4 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Targetcancer Foundation Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 01/2024, Targetcancer Foundation Inc generated $676.5k in total revenue. This represents relatively stable growth, over the past 9 years the organization has increased revenue by an average of 7.1% each year. All expenses for the organization totaled $797.7k during the year ending 01/2024. While expenses have increased by 12.1% per year over the past 9 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2016, Targetcancer Foundation Inc has awarded 12 individual grants totaling $684,003. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2024
Describe the Organization's Mission:
Part 3 - Line 1
SUPPORT FOR RESEARCH INTO THE CAUSES AND TREATMENTS OF RARE CANCERS.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE SPECIFIC PURPOSES OF THE ORGANIZATION ARE TO RAISE AWARENESS OF AND SUPPORT FOR RESEARCH INTO RARE CANCERS, AND TO DIRECTLY SUPPORT PATIENTS AND FAMILIES FACING RARE CANCERS. THIS WAS ACCOMPLISHED IN THE FISCAL YEAR THROUGH THE ONGOING OPERATION OF A RARE CANCER PRECISION MEDICINE CLINICAL TRIAL, AND THROUGH OTHER PROGRAMS. IN 2020, TARGETCANCER FOUNDATION LAUNCHED A RARE CANCER PRECISION MEDICINE CLINICAL TRIAL CALLED TCF-001 TRACK (TARGET RARE CANCER KNOWLEDGE). TRACK IS A 400-PATIENT CLINICAL TRIAL STUDYING GENOMICS AND PRECISION MEDICINE IN RARE CANCERS, PROVIDING PATIENTS WITH CRITICAL PERSONALIZED GENOMIC DATA ABOUT THEIR CANCER AND TREATMENT RECOMMENDATIONS FROM A PANEL OF FIELD LEADERS, AND ALSO GENERATING RARE CANCER RESEARCH DATA. TRACK IS DEVELOPED, SPONSORED AND MANAGED BY TARGETCANCER FOUNDATION, AND IS CURRENTLY OVER HALFWAY THROUGH ITS ENROLLMENT OF PATIENTS WITH RARE CANCERS AND CANCER OF UNKNOWN PRIMARY.IN 2023, TARGETCANCER FOUNDATION HELD A MAJOR SCIENTIFIC MEETING- THE THINK TANK ON ADVANCING PRECISION MEDICINE IN RARE CANCERS. THIS UNIQUE, INNOVATIVE MEETING UNITES KEY STAKEHOLDERS INCLUDING CLINICIANS, RESEARCHERS, GOVERNMENT, INDUSTRY, AND PATIENTS AND ADVOCATES. THIS MEETING IS SPECIFICALLY DESIGNED TO PROMOTE COLLABORATION, INFORMATION-SHARING AND IDEA GENERATION IN AN EFFORT TO DEFINE RESEARCH PRIORITIES, FOSTER NEW COLLABORATIVE EFFORTS ACROSS INSTITUTIONS, AND ULTIMATELY PROPEL THE FIELD FORWARD.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Jerry Alderman Director | Trustee | 1 | $0 |
Jennifer Levin Carter MD Director | Trustee | 1 | $0 |
Cj Chapman Director | Trustee | 1 | $0 |
Samuel Davenport Director | Trustee | 1 | $0 |
Janet Fine Ms Director | Trustee | 1 | $0 |
Mary Pat Lancelotta Director | Trustee | 1 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $674,113 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $674,113 |
| Total Program Service Revenue | $0 |
| Investment income | $2,338 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $676,451 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $25,000 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $221,934 |
| Compensation of current officers, directors, key employees. | $55,484 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $88,928 |
| Pension plan accruals and contributions | $1,517 |
| Other employee benefits | $0 |
| Payroll taxes | $22,397 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $12,449 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $269,626 |
| Advertising and promotion | $1,683 |
| Office expenses | $11,536 |
| Information technology | $8,181 |
| Royalties | $0 |
| Occupancy | $22,345 |
| Travel | $2,820 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $66,788 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $4,250 |
| All other expenses | $38,220 |
| Total functional expenses | $797,674 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $65,499 |
| Savings and temporary cash investments | $450,174 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $8,235 |
| Other assets | $0 |
| Total assets | $523,908 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Net assets without donor restrictions | $523,908 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $523,908 |
Grants Awarded
Over the last fiscal year, Targetcancer Foundation Inc has awarded $101,000 in support to 3 organizations.
| Grant Recipient | Amount |
|---|---|
MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER PURPOSE: To support laboratory research of cholangiocarcinoma | $35,000 |
DANA-FARBER CANCER INSTITUTE PURPOSE: In support of esophageal cancer research | $50,000 |
CONQUER CANCER FOUNDATION PURPOSE: To support cholangiocarcinoma research through the Young Investigator Award | $16,000 |